Viz.ai is a leader in applied artificial intelligence in healthcare. Our mission is to fundamentally improve how healthcare is delivered globally through intelligent software that promises to reduce time to treatment and improve access to care. Our flagship product, Viz LVO, leverages advanced deep learning to communicate time-sensitive information about stroke patients straight to a specialist who can intervene and treat. In February 2018, the U.S. Food and Drug Administration (FDA) granted a De Novo clearance for Viz LVO, the first-ever computer-aided triage and notification platform. In 2020, Viz LVO became the first AI software to receive approval from CMS. We are a distributed team with offices in San Francisco, Tel Aviv, and Heerenveen. We are backed by leading Silicon Valley investors, including Kleiner Perkins, Google Ventures, Green Oaks, CRV, and Threshold Ventures.